Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
Trial Details
- NCT ID
- NCT06697301
- Phase
- PHASE2 / PHASE3
- Sponsor
- Eikon Therapeutics
- Status
- RECRUITING
- Cancer Type
- Melanoma
- Interventions
- EIK1001
- Pembrolizumab (KEYTRUDA® )
- Locations (sample)
- Chandler, Arizona, United States|33.30616,-111.84125
- Hot Springs, Arkansas, United States|34.5037,-93.05518
- Los Angeles, California, United States|34.05223,-118.24368
- Colorado Springs, Colorado, United States|38.83388,-104.82136
- Hialeah, Florida, United States|25.8576,-80.27811
Key Eligibility Criteria
- To be eligible for inclusion in this study, participants must:
- Be ≥ 18 years of age on the day of signing of informed consent.
- Have a life expectancy of at least 3 months.
- Have histologically or cytologically confirmed Stage 3 (unresectable) or Stage 4 metastatic melanoma per AJCC 8th ed. and be eligible for standard …
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Melanoma Trials on Trialify →